Fort Myers, Florida, United States, October 14, 2026
Florida Cancer Specialists & Research Institute (FCS) has announced its contribution to the clinical research supporting two significant U.S. Food and Drug Administration (FDA) approvals for targeted cancer therapies, advancing treatment options for patients with advanced breast cancer and metastatic pancreatic cancer. The developments highlight the importance of early-phase clinical trials and long-term oncology research in translating scientific discoveries into new treatment approaches. FCS participated in the early clinical development of camizestrant, an oral therapy designed to address hormone therapy resistance in certain breast cancers, and daraxonrasib, a targeted therapy for certain patients with metastatic pancreatic cancer. According to the institute, these milestones reflect years of research conducted through its drug development units and wider clinical research network, reinforcing the role of community-based oncology centers in advancing cancer treatment.
Camizestrant Advances Targeted Breast Cancer Treatment
The FDA granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor for certain adults with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer whose tumors develop an ESR1 mutation during treatment. These mutations can contribute to resistance to endocrine therapy, making disease management more challenging for patients with advanced breast cancer. Camizestrant is an oral selective estrogen receptor degrader (SERD) designed to block estrogen receptor signaling, which can drive the growth of hormone-sensitive breast cancer cells. CDK4/6 inhibitors work through a complementary mechanism by interfering with proteins that regulate cell-cycle progression. Combining these approaches aims to help control cancer growth in patients whose disease develops resistance to existing hormonal treatment. FCS contributed to the therapy’s early development through a first-in-human Phase 1 dose-escalation study conducted at its Sarasota Drug Development Unit in 2019. The institute subsequently participated in Phase 3 clinical research evaluating camizestrant. According to the reported trial findings, patients who switched to camizestrant achieved median progression-free survival nearly twice that of patients in the control group. These results helped establish the clinical evidence supporting the therapy’s development and potential role in treating ESR1-mutated breast cancer.
Daraxonrasib Targets Metastatic Pancreatic Cancer
FCS also contributed to the development of daraxonrasib, a targeted therapy for certain adults with metastatic pancreatic cancer. Pancreatic cancer remains a major therapeutic challenge, particularly after the disease spreads beyond the pancreas, when treatment options may be limited and long-term outcomes are often poor. The institute participated in early-phase clinical trials that helped evaluate the candidate’s safety and potential effectiveness. These studies generated evidence that supported subsequent clinical development and contributed to the regulatory approval process. In the pivotal trial cited in the announcement, patients treated with daraxonrasib achieved median overall survival of 13.2 months, compared with 6.7 months among patients receiving standard-of-care chemotherapy. Median overall survival measures the time by which half of the patients in a study have died, making it an important endpoint for assessing treatment outcomes in advanced cancer. The reported findings highlight the potential importance of targeted treatment strategies for patients with metastatic pancreatic cancer. However, treatment selection depends on the approved indication, individual patient circumstances and guidance from the treating oncology team.
Advertisement
Clinical Research Accelerates Oncology Innovation
These milestones demonstrate how early-phase clinical trials can contribute to the development of new cancer therapies. FCS operates a community-based oncology research program with clinical trial access across nearly 30 locations in Florida, including specialized drug development units in Sarasota and Central Florida. Its research activities span first-in-human studies, dose-escalation trials and later-stage clinical investigations. Through collaborations with the Sarah Cannon Research Institute (SCRI) and Paradigm, Inc., FCS works to expand access to clinical trials and support the evaluation of emerging cancer treatments. Its research program conducts more than 180 active clinical trials annually, according to the organization’s announcement. FCS leaders emphasized that the two approvals demonstrate the value of sustained investment in clinical research and collaboration between investigators, research organizations and pharmaceutical developers. The institute continues to participate in studies exploring additional applications of approved and investigational therapies across breast cancer, pancreatic cancer and other tumor types. For oncology research, the developments underline the importance of precision medicine, targeted therapies and clinical trial participation in addressing unmet medical needs. Continued research will help clarify the long-term benefits, safety profiles and appropriate clinical use of these treatments, while supporting future advances in cancer care.
Source: Florida Cancer Specialists press release
